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INTRODUCTION
Nosology and Etiology
Many discrete entities have been grouped together
as the schizophrenic or affective disorders.

An anology

for this formulation has been recent findings on mentally
deficient patients in which the mental deficiency can be
caused by a number of separate discrete entities, each
of which is characterized by a distinct, genetically
controlled, biochemical abnormality.

It must be recog-

nized that the problem of schizophrenia and affective
disorders may not be solved so sirnply and that multifactor or field theories of etiology may be more compatible wlth the clinical and experimental data.

Such

theories imply simultaneous occurance of experiential.
and constitutional biochemical factors in order to give
rise to a given clinical state.
Genetics
The genetic studies of twins suggests a hereditary
basis for a number of psychiatric disorders and gives
support to biological factors in mental illness.

The

"inborn error of metabolism" and "one gene one enzyme"
hypotheses of Garrod and Beadle upon which contemporary
biochemical thinking is based, has achieved substantial

-2support through the discovery of discrete enzymatic
slona underlying many inherited diseases including
mental deficiencies.

However. the permanency of a detect-

Hble enzyme defect cannot be assumed because it is possible that

certHi~

genetically controlled enzyme defects

may be transient and_ occur only in response to specific
environmental conditions or criticl::1.1 str:lges in development.

These may still give rise to permanent structural

changes in the nervous system and in learning experience ..
consequently giving rise to behavioral change without
detectable enzyme abnormality.

Other proponents of an

organic etiology of schizophrenia and affective disorders
ha.ve suggested acquired abnormali ties such as autoimmune
resctions or viral infections. but these are not generally
a.ccepted by contemporary investiga.tors. 1
The Catecholamine Hypothesis
Biochemical studies of affective disorders comprise an extensive literature which until recently has
contributed little to the understanding

b~

the bio-

chemical mechanisms which may underly these disorders.
Recently. the introduction of a number of drugs capable
of producing both profound mood changes in human
subjects, and alterations of brain amines in animals,
has focused interest on the possibility that a disorder
in brain metabolism may underlie affective illness.
therefore will present in this thesis recent selected
studies involving drugs affecting amine metabolism

I

-3"ltJ"hich support the catecholamine hypothesis of affective
disorders.

This hypothesis is based on the proposal

that depressions are related to an absolute or relative
depletion of catecholamines at functionally important
sites in the brain and that elations may be associated
with an excess.

Other areas of research that will be

mentioned include the use of lithium carbonate in
manic depressive psychosis. and carbohydra.te metabolism
in depression. 2

-4Review of Monoamine Metabolism
Norepinephrine is a naturally occuring catecholamine
located in the central nervous system, the peripheral
sympathetic fibers. and in the adrenal medulla.

Both bio-

chemical and histochemical methods have demonstrated
that norepinephrine (NEP) and the neurohumors, dopamine,
and serotonin are concentrated in specific structures
throughout the brain ie .• the hypothalamus, caudate, and
lentiform nuclei.

NEP functions as a neurotransmitter

substance in the peripheral system.

It has been suggested

that NEP may function also as one of the central neurotransmitter substances in the brain.

NEP is stored in

granules in nerve endings and is present in body fluids.
NEP is synthesized from tyrosine with dihydroxyphenylalanine (dopa) and dihydroxyphenylethylamine (dopamine)
as the two intermediate steps.

More specifically.

tyrosine, which is plentiful in the plasma. is hydroxylated to 3,4-dopa which is converted by dopa decarboxylase
(aromatic 1 amino acid decarboxylase) to dopamine.
is hydrox,ylated to form NEP in the granules.

This

The rate

limiting step. however, is the tyrosine to dopa step.
NEP is being continuously synthesized and broken down.
stored and released, and various storage pools are in
dynamic equilibrium. 3
The breakdown of norepinephrine occurs along at
least tvw known pathways.

One involves ini tial

oxidation by monoamine OXidase, and the other involves
initial o-methylation by catechol o-methyl transferase.

-5NEP is

met~bolized

inside the cell by oxidase which

converts it to )-methKy-!+-hydroxy-mE1..ndelic acid (VNiA)
through the intermediate metabolj_ te. :3, 4-dihydroxymandelic 8.cid.

Circulating NEP and NEP rele;:.,_sed by

nerve stimlllation are metabolized to VhA by catechol
a-methyl transferase through the intermediate metabolite
normeta.ne phrine.
Route of
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Evidence from a large nU"lber of sources suggests
that NEP is functionally stored in at least two different
pools. a loosely bound t3.nd firmly bound pool.

Evidence

for th18is provided by the differential rates of
Ur)t.9.!z,:e and release of exogenous NEP and the differential
release of NEP and various drugs.

Of particular

relevance to the hypothesis is the suggestion that

-6reserpine releases mostly l'iJEP from the firmly bound
store which is subsequently deaminated to s. functionally inactive metabolite.

In addition there is a

store of NEP which is relatively resistant to the action
of reserpine alone, but can be released by electrical
nerve stimulation.

Both biochemical and histochemical

studies indicate that it is difficult to deplete nerves
of catecholamines through repeated stimulation.

NEP is thought to be conserved by a process through
which the nerve takes up the NEP from the synaptic area
9nd returns it to its stores.

The resynthesis and

rebinding mechanisms are able to keep up, even with very
rapid rates of nerve stimulation.

Some investigators sug-

gest that NE? as well as dopamine and serotonin all
function directly as trsnsmitter SUbstances while others
postulate that one or more of them may act as modulators
or regulators of synaptic transmission mediated by some
other direct transmitter, for example, ACTH.

Inhibition

of either rebinding or synthesis results in catecholamine depletion in nerves.

The action of catecholamines,

released by nerve stimulation is terminated in the
synaptic area by rebinding to the cell membrane of the
nerve end plate iNi th resul tant concentration of NEP
ltvi thin the nerve cell.

Intracellular deamination by

MAO, within the nerve cellon the other hand, inactivates
NEP to Vl'tIA and extrudes this inactivated form outside

the neuron.

Active NEP in the synaptic cleft free of

the receptor site is also inactivated to normetanephrine
by em'IT. 4

-7Effect on NEP of Drugs Influencin.,g
Depression
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,
The basis of the catecholamine hypotheSiS of
affective disorders is that depressions are thought to
be associated with an absolute or relative deficiency
of catecholarnines in functional

important sites in the

-8brain, and that elations may be associated with an
excess of catecholamines. notably norepinephrine.

The

postulated pharmacological mechanisms of action of certain
drugs give credance to this hypothesis.

It has been

shown repeatedly that high doses of reserpine markedly
depletes NEP from the brain and causes depression in
man,ilethargy and sedation in animals.

The mechanism

of action may involve interference with NEP storage in
the cytoplasmic granules or at the axonal membrane
resulting in either prevention of rebinding or release
of NEP from its storage granule into the intracellular
sap, thus exposing it to enzymatic attack by MAO.

It

is then metpbolized by intracellular deamination.
Methyl dopa depletes brain NEP by acting through its
metabolite methylnorepinephrine, which displaces NEP
from its storage si te s.

\,-Jhen conversion of methyl do pa

to its metabolites is prevented by the appropropriate
decarboxylase inhibitors, methyl dopa has no NEP
depleting properties.

6

Imipramine and desmethylimipramine (mE) prevents
reserpine induced depression by blocking the rebinding
or physiological uptek:e of endogenous NEP at the axonal
cell membrane.

If NEP is released by nerve stimulation.

imipramlne acts ln such a way as to block the reuptake
of this free NEP by the nerve.

The MAO inhibitors act

by inhibiting the intracellular deamination of NEP, thus
increasing the amount available for extrusion to the
receptor site.?

-9Lithium salts have been recently well established
~s

effective agents in the treatment of manic and hypo-

manic st8tes.

Hhen administered prophylactically to

patients with recurrent depressions, lithium chloride
has been reported to decrease the frequency of attacks
and to abolish them altogether, just as it does in
recurrent mania.

In contrast to its well-established

direct therapeutic effect in the treatment of the
symptomatic phase of mania, however. lithium has little
or no direct antidepressant effect when administered
during the symptomatic phase of depression.

The postulated

mechanism of this ion is that of increasing the intraneuronal deamlnation of NEP thus decreasing the NEP
available at adrenergic receptor sites.

However, in cor-

relating the clinical effects of lithium with biochemical
findings, it is necessary to distinguish the direct
therapeutic action of this drug in mania from its
prophylactic action in depreSSion, since different mechanisms may be operative. 8
Summary of the Pharmacological Observations
Compatible with the Catecholamine Hypothesis
of Affective Disorders.
prug

?eserpine

Effects in IVIan

?edation
depression

,Animal Behavior

sedation

Effects on
catecholamine
in animal
brain
depletion
"{intracellular
deamination)

-10-

Tetrabenazine

sedation
depression

sedation

de pletion
(intracelular deaminatlon)

Amphetamine

stiJ'lulant

stimulatlon
excitement

Releases
NEP onto
receptors
Inhibits cell
uptal{e of

NEP
HAO irthibl tors

t [1 i

antidepressant

excitement
increases
preven t S Emd
levels
reverses reserpine
induced sedation

treatment of
mania

increases intracellular deaminatlon of
NEP--decreases
NEP at
receptors

Al )11.8 -iD8 th,yl
para tyrosine

sedation (trans~sedation in
lent) with
some studies
hypomania upon
vii thdrawl

inhibits
synthesis

Imiprarnine

antidepressant

lnhibits
cellular
uptake of
NEP potentiates
action of'
NEP at
periphery

11m

sa 1

t

8

prevents reserpine
induced sedatio~
potentiation of
amphetamine
effects

-11-

Urinary excretion patterns have also contributed
confirmatory evidence in favor of the catecholamine
hypothesis.

Urinary excretion of normetanephrine which

may reflect noradrenergic activity. showed a gradual
increase during the period of definitive clinical
improvement in depressed patients treated with imipramine.
These findings suggest that noradrenergic activity may
gradually increase during clinical improvement from depression, and that noradrenergic activity may be relatively
decreased in retarded depression and increased in mania. 10
In another study by Maas, Fawcett, and DeKirmenjian
using carbon labeled NEP injected into the lateral ventricle of a cat. it was shown that a significant fraction
of urinary )-methoxy-4-hydroxyphenylglycol (MHPG) is
derived from the brain pool of NEP while urinary

3-

methoxy-4-hydroxymandelic acid, metanephrlne, and perhaps
normetanephrine, reflect catecholamine metabolism in
peripheral adrenergic tissues.

It was noted that little

normetanephrlne enters the body pool from the brain and
that urinary levels of NEP principally reflect the metabolism of NEP by tissues other than the brain.

This

study suggests that a significant fractio:'} of (l'iIHPG) is
derived from the brain pool of NEP, while VI1A metanephrlne and normetanephrine reflect catecholamine
metabolism in peripheral adrenergic tissue.

In support

of the catecholamine hypothesis wes the fact that there
were no statistically significant differences between
patients and control groups for levels of metanephrine

-12or normetanephrlne in urine.
group·

It was found that the

of depressed patients had significantly lower

levels of (MHPG) in urine than did the control
subJects. 11
Steroid» CaLboh,ydrate and Electrolyte
Metabolism in Depression
In a st')dS by Curti s. Cleghorn. and Sourkes, a
correlation was found between urinary excretion of
adrenaline and noradrenaline.

The data suggest that

in affective states of depression, noradrenalin is
excreted preferentially in comparison with adrenaline
and corticoids. while corticoids are excreted preferentially in states of anxiety, ·in subjects whose difficulties
were disorders of thinking or behavlor. 12

Results of

oral glucose tolerance tests in a study by Herzberg,
Copper, and Marks revealed no significant difference
between the fasting levels of the patients tihen depressed
and on recovery.1]
The Use of Li thill.m Carbonate
Nineteen years of clinical experience have shown
lithium salts to be effective therapy for acute manic
attacks and more recent evidence suggests that it can
prevent recurrent psychotic depressive or manic episodes.
Lithium's effectiveness was first observed in 1949. by
John F. Cadet who noted that guinea pigs given lithium
c .14
letha.r .'"':-l"
ca rb. ona te b ecame slee py and
.
5

He then

-13tried the compound on ten manic patients and found that
it caused their excitement to disappear.

Its action in

acute mania has been confirmed in controlled studies
by Schou. Gershon. Yuw'iler, and Maggs.

Li thi urn was

found to be spectfic in that it removes the hyperactivity and elation without interfering with normal
processes. 15

Since the work of Cade, there have been

a number of articles tn the world literature from
Australla. Denmark, England, France, and Russia concerning the use of lithium for the treatment of manic
behavior. 16 Of these, the enthusiastic Scandinavian
report by Professor Schou, 1959. reviewing ten years of
lithium therapy. endeavors to proclaim its epochal
character.

K.ingston from Canada, and particularly

Gershon and Yuwiler. an Australian-American team, gave
it a most notable introduction to North AmeriCa in

1960. 17

Despite its well-demonstrated usefulness,

lithium has not been much studied or used in the United
States.

This is due in part to the bad name that

lithium chloride developed in 1949 when it was used
8S

a salt substitute for cardiac patients, a use that

led to se'\.Teral deaths from lithtum poisoning.

The

introduction of tranquillzers probably further pushed
lithium into obscurity in this country.lS

-14Reports on Manic Patients Treated with
Lithium and Given No Other Physical Therapy
Author
Cade (1949)

Total

Improved

Unimproved

10

10

0

3

3

0

27

26

1

4

3

1

4

4

o

3

1

2

o

2

G1esinger (1954)

2 1.L

15

6

Schau aY1d associates (1955)

48

39

9

Sivadon and Charoit (1955)

10

10

o

Tev1ie and associates (1955)

25

20

5

10

9

1

37

34

3

1l.j,

13

1

24

8

119

91

28

17

16

1

4~~

-E

-11

Despinoy and de Romeuf (1951)
Noack aad Trautner (1951)
Reyss

ion and Grambert (1951)

Desc

a(1d Denis (1952)

Duc

[ilaurel (1953)

Givstino (1953)

Gershon

Trautner (19j6)

'3

Ric (1956)
associates (1958)
Bell1. r',3: (1959)
SC~lOU (1959)

Ki ngsto"18 (1960)
_Harti~ay;
.•". D~.J..

(1963)
....r....

In a study by Schagenhauf

t

80

352

TU:Jin. and t-lhi te. I i thlum

carbonate was used in the treatment of ten hospitalized
patients with acute, severe manic excitement.

Patients

were given 300 mg. four times daily until improvement
or side effects were ap})3rent.

Patients viTel'e maintained

on 0.6 to 1.2 gm of lithium carbonate daily in divided

-15doses.

The seru.lTl levels never exceeded 1.5m eq/L and

usually were below 1.0m eq/L.

As suggested by other

investigators, additional HaCl was given because when
given to humans, lithium causes a sodium diuresis which
results in

51

temporary hyponatremia.

All the patients

aged 21-59. seven females and three males, had a favorable response to lithitoo therapy.

Most had failed to

respond satisfactorily to previous intense phenothiazine
therapy.

Improvement

v~as

noted usually on the fourth

or fifth day of treatment and always before the tenth
day.

Excitement, irritability, and euphoria gave

way to more appropriate and less irritable affective
state, a decreased r[lte of speech and stream of thought.
and decreased psychomotor activity.

In this study

no attempt was made to correlate serum lithium level
and clinical improvement or tOXicity.

None of the patients

experienced any recurrence of manic illness or depressive
sYJ'11ptoms as long as he was remained on maintainence
therapy.

Of three patients who stopped taking a main-

tainence dose, two prombtly went into acute manic
excitement in fourteen days.
There is evidence that in addition to controlling
symptoms, one of the great values of lithium therapy
is its capacity to prevent recurrences of either manic
or deoressive symptoms when used for extended periods
of time on maintainence dosages.

Hartigan 20 reported

that he had maintained patients on dosages of lithium
without an effect for up to six years.rhis study

-16suggested the use of lithium for learning more of the
nature of manic depressive disorders. 21
In a study at the New York State Psychiatric
Institute by Warton and Fieve, a total of nineteen
patients with manic-depressive psychosis, manic phase
were treated with lithium between

1959 and 1965.

The

oatients selected for trec::,tment manifested hypera.ctivity.
pressure of speech, and elation state. 22
Psychiatric Historl of
Prior manic
one
two to
six to
ten or

attacks
five
nine
more

19 Patients

Nales
2

Females
2

6

7

0

0

1

1

2

o

1
2

1

4

7

5

Frior treatment
Electroconvulsive therapy
Improved
Not improved
Phenothia7ines
Improved
Not improved
Allergic

1

1

After an observation period of ten days, the
patients were treated with lithium carbonate for a
two-week period at a dosage that maintained the blood
level between 1-2 meg./liter.

After this period, a

maintaince level of 0.5 to 1.0 meg./liter was utilized.
I

The dosage was tapered from 1800 mg./day to 900 mg./day
after maintainence levels were achieved.

Careful

monitoring of blood levels was done to prevent knolAm
toxic effects.

These have been elaborated by Schon,2)

-17Gershon, and Maggs and include gastrointestinal upset,
tremor, atakie. dizziness, decreased blood pressure, and
rarely, epileptiform seizures.

At high levels in vitro,

lithium may block carbohydrate and amino acid metabolism by affecting specific enzyme systems; at high
levels in tissue culture, lithium may affect astrocyte

met~bollsm.24

No information is available as to lithium's

actton at these doses in man.
In the 25 trials on 19 patients responses l;Jere
separated into four categories:

good response, equivocal

response, inadequate trial, and poor response.
Manic Attacks in 19 Patients Treated
With Lithium Carbonate
Quality of Response

Number of 'rria1 s

Good

11

Equivocal

6

Inadequate

3

Poor

5

An attack W9S considered aborted when a significant change was noted in all three parameters under
observation. ie.. decreased motor hyperactivi ty, altered
mood, and decreased pressure of speech.

The prognosis

and natural history of the individual manic attack are
uncertain.

Strecker cownents that "between ages 15 and

25. the average duration is three to six months with
future attacks in general of greater length".
and Ke1b state the

fI~verage

Noyes

duration of the attack is

-18six months.

iI

Arieti comments that "the

~)rognosis

is

almost always good, but uncertain as to recurrence.»
In this study the shortening of the duration of the
attack was used as the measure of efficacy and an
unequivocal and conservative 44 percent improvement
after two weeks on lithium was noted.

If the equi-

vocal response group were included, 17 out of 25

(68 percent) improved.

Maggs used intensity of the

symptoms of the attack as measured by the Wittenborn
scale to evaluate the effects of lithium treatment;
he reported his results as statistically significant
compared with placebo in 18 out of 28 patients treated.
Schou, in his data, demonstrated decreased frequency
of attacks as well as the capacity to abort attacks in

39 of 48 patients treated or approximately 80 percent
improvement including both his "positive effect» groups
and "possible effect" groups.-;;>5
The impression of these investigators was that a
closer correlation between observable body activity, social
behavior, mood, speech, and metabolism would be needed
to further evaluate the effects of lithium.

They noted

that the reports by Gibbons 26 and Coppen of increased
exchangeable sodium and ionic shifts as well as changes
in electrophysiology as primary biochemical lesion or
eDiphenomena remains open to question.
Lithium-Mechanistic Speculations
The site of action of lithium has been suggested
as at the thalamic and reticular level,27 but this

-19ignores any relevance to the replacement of other
anions within the cells by lithium.

It is postulated

that the curative action of lithium may be the result
of its intervening to reduce free energy change, through
potassium or

~odium

displacement by lithium.

It may

act through enzyme inhibition of ATP energy production
and serve to recover lost hormonal control and direction
of energy thus preventing an uncontrolled production
of free energy in muscle.

Lithium could be repla.clng

intracellular fluid sodium, the loss of which helps
to stabilize hormonal control of fluid secretion that
otherwise fluctuates in periodic illness, the patient
being usually polyuric at the beginning of a manic
28
attack and oliguric during depression.
Two reports
seem related to such possibilities:

the observation of

Batycharya that the action of lithium is similar to the
action of insulin in promoting a rapid uptake of glucose
fro~

extracellular fluid into the cell, and the 6bser-

vation of Carr and SoJler that lithium has a very large
electro-osmottc effect on water transportation in
macrocellular experimental models and probably also in
true mosaics. 29
In a reViell-T of pending biochemical questions of
lithium therapy, Greenspan (1968) cited several areas
of observation.

His studies demonstrated that in

depression there is an increase in sodium retention
compared with the recovered state.

This is paralleled

by an increase in 17-hydroxycorticosterold and 17ketosteroid levels.

Such elevations were not usually

-20observed in manic patients.

Studies of sodium distribution

and 24-hour exchangeable sodium in manic and depressed
patients who responded to lithium revealed an increased
24-hour exchangeable sodium in depression. 30
Overton (1902) noted that if sodium were removed
from the bath surrounding frog muscle it would no longer
respond to electrical stimulation.

Lithium was the only

ion substituted for sodium that restored the muscle's
excitability.

Keynes and Swan (1959) demonstrated in vitro

that lithtum moves into muscle flbers like sodium, but does
not leave as readily.

Moreover. the egress of lithium

was not bloc\';-ed by removal of potassium which suggests

that sodium and lithium entered alike but did not share
the samepuf1!J mechanism for extrusipn.

It

vJaS

found

that lithium accumulated within muscle fiber and eventually rendered it inexcitable.

Zerahn (1955) found

that lithium was actively pumped across frog skin. but
unlike sodium. accumulated in the epithelium.

Similar

findings were noted in isolated nerve observations but most
of these were done with high concentration of lithium in
vitro.

The implication is, however, that the action of

lithium may be due to tts effect upon sodium metabol.
31
Ism.
One of the most

consist~nt

flndtngs has been that of

an increase of 5~% in the amount of intracellular sodium
together wi th a sffiEtll but unknoiJm amount of exchangeable
bone sodium.

This

W2S

found to return to normal after

recovery (Coppen, 1963).

Low concentrations of intra-

-21cellular potassium were found in depressed patients,
but this did not alter
Coppen. 1956).

~ith

clinical improvement (Shaw,

These changes are for body electrolytes

as a whole. and there is no direct evidence that paralell changes take place in the central nervous system.
If camparable events did occur in the brain, cerebral
excitability would be much affected by reduction of both
resting and action potentials (Shaw. Coppen, 1966).

In

addition to these changes in electrolyte distribution,
a reduction in extracellular water in depression has
been observed in investigations using either the
thioc,y-anate space or the volume of radioactive bromine.
In mania, distribution studies have revealed similar
(but greater) changes in the distribution of sodium
compared with those found in depression; the average
being twice normal.

'~2

J

-

Tryptamine Metabolism in Depression
Coppen, Shaw, and Farrel (1963) showed that large
doses of DL- tryptophan (214 mg./kg. body weight)
given to depressed patients receiving tranylcypromine
(a NAO inhibitor) potentiated the anti-depressive
effects of the drug.

This also increased the level

of 5-hydroxytryptamine (5HT) and tryptamine in
the rat.

-22f'letabolic PathTiJa.ys Investigated
l

transamination

Indolepyruric acid

1

decarboxylation
------.".~

Try ptamine --;.. Indole- 3MAO
acetic acid
(urinary excretion
Hydroxylation
dec, reased in
depression)
decarboxylation
MAO
5-hydroxytryptophan
;.r 5-hydroxytryptamine --+ 5-hydroxy(5 RTP)
(A possible
(5 HT)
indole acetic
defect
(decreased in
acid (5 HIAA)
here?)
depression}
(reduced in
spinal fluid
in depression)
(Abnormal Tryptophan metabolism
is implicated in depression)

Trytophan

1

In an initial investigation by Coppen, Shaw and
Malleson, (1965) the rate of decarboxylation of 5'
t op h an (5 H'P'P)
_-'h,y d roxytryp

,'laS

s t:. . u d'1.e d 'b y

.
me'~surlng

tn' e

expiratory rate of 14C02 following the injection of

5 RTF labelled

with 14C in the carboxyl group.

The

resu]ts showed that the rate of expiration of 14C02
NBS reduced during depreSSion, probably because of a
slower rate of decarboxylation of

5

RTP to form 5 HT.

In a carefully controlled study by Coppen, Shail?

l'lalleson,

Eccleston, and Gundy (1965) tryptamine and IAA excretion
was investigated in 13 severely depressed patients
before and after recovery
tryptamine excretion

vlaS

fro~

their illness.

Urinary

found to be abnormally 101'11"

during the illness and rose by an average of 70% to
Gtpproximately normal values after recovery.
IAA showed no significant cha.nge.
not related to urinary

Urina.ry

The findings WBre

and volume, nor to diet.

-2)Plasma try ptophan levels did not vary signif ican.tly.
Unexpectedly. intravenous tryptamine given to depressed
patien ts receiving IvLAO inh1 bi tors shovved that this
procedure, unlike that with tryptophan, had no
therapeutic effect.
W9S

One explanation for this discrepancy

that tryptamine is inert in man or th9t a species

difference in the blood-brain barrier exists between
man and the smaller animals.

5-HTP, which passes the

blood-brain barrier and reverses reserpine depression
in small laboratory animals (Hess and Doepfner,

1961)

also has little or no antidepressive action in man
(Kline, Sacks, and Simpson,

1964).))

5-HT and tryptamine

are produced in the brain only from tryptophan. the
most likely normal precursor of these amines in the
CNS.
An Alternative to the
Catecholamine Hypothesis?
The studies of Dewhurst and Marley

(1964) with

particular reference to the use of the young chick
concluded that cerebral amines fall into two nain
functional groups.

Excitant (Type A) amines have the

general formula R. CH2' CH2' NH2' where R is a fatsoluble and planar hydrocarbon (e.g., indolyl or
phenyl).

All amines of this group produce all the

phenomena of the alert state both behaviorally and
physiologically with tryptamine being the most potent
phYSiological agonist.

Depressant (Type C) amines

-2Lj,-

are of the general structure Hi. CH(OH). CH2. Nil. CR).
t
weret
Hi ·lS 1iliaer
so 1 u bl e (e.g •• catechol).
h

Such amines

produce all the phenomena of drowsiness or sleep, adrenaline being the most potent physiologic agent.

Type.A

(excitant) or type C (depressant) activity depends primarily
on lipid solubility and not on "whether a substance is an
indole or catechol or ohenylethylamine.

Dewhurst and

Marley found that type A amines act through a specific
receotor identical to the peripheral tryptamine receptor;
type C amines are mediated by a receptor
peripheral alpha rece9tor.

si~ilar

to the

Thus, the known alerting

effect of catecholamines has been shown to depend on
hypertensive responses

second"~Jry

pheral alpha receptors.

to stimulation of peri-

It has also been shown that a

small group of amines (type B), which includes

5

HT, are

biphasic, having the ability to act on both A and C
receptors sequentially.

Depressions, thus are related

to a deficiency of type .A amines or

~alfunctions

of the

A receptor, vJhereas in 1'1ania the converse would be true. 34
Objections to this hypothesis were raised by H.
hreil-i'lalherbe of N.I.l'I.H.

He states that Dewhurst's

view of depressive psychosis is due to a deficiency of
';type Ail amines, presumably tryptamine, and it must be
inferred that tryptamine, has a role as a nervous
transmitter.
to

ShOVf

To sUbstantiate this it would be necessary

that tryptamine. has been found in the normal

brain; only small amounts vJ.ere found after combined

-25administration of L-tryptophan and M80 inhibitors.

35

The current concept of the alerting effect of brain
catecholamines is based on the effects of dopa and
dexa~phetamine.

Dopa, which crosses the blood-brain

barrier, is supposed to act as a precursor of brain
dopamine and NEP; the action of amphetamine is also
9ssumed to be indirect and mediated by dopamine and

NEP.

Dewhurst proposes a direct action for dopa

and amphetamine.

In doing so he overlooks

t~e

following;

(1) the dopa effect is potentiated by MAO inhibitors and
blocked by dec8rboxylase inhibitors (Carlsson, Lindquist.
Magnusson,

1957); also, the alerting effect of a series of

related amino acids is correlated with their rate of
decarboxylation (Blascho and Chrusciel,

1960): (2) the

central action of amphetamine is blocked when catecholamine
synthesis is inhibited (Randnup,

1966).

Similarly. the

antidepressive action of impramine has been shown to
depend on a 'lfifell-stocked store and normal synthesis of
brain catecholamines (Sulser, Soroko,

1965).

Whether

the alerting effects of epinephrine and NEP are purely
of peripheral origin is still controversial (Dell.

1960).35
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